Levodopa Carbidopa Intestinal Gel (Duodopa) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
Levodopa-Carbidopa Intestinal Gel (LCIG), marketed as Duodopa (Europe) and Duopa (US), is a continuous infusion therapy for advanced [Parkinson's disease](/diseases/parkinsons-disease) that delivers levodopa and carbidopa directly to the small intestine via a percutaneous endoscopic gastrojejunostomy (PEG/J) tube. This formulation bypasses gastric emptying variability and provides more stable plasma levodopa levels compared to oral medications, dramatically reducing motor fluctuations and dyskinesias.[@nyholm2021] [@othman2019]
LCIG was developed to address the "levodopa problem" - while levodopa is the most effective medication for Parkinson's motor symptoms, chronic oral dosing leads to increasingly erratic absorption, causing unpredictable "on" and "off" states. Approved by FDA in 2015, LCIG represents a major advancement in continuous dopaminergic delivery. [@fernandez2020]
Mechanism of Action
Continuous Dopaminergic Stimulation
The gel formulation contains:[@othman2019] [@zibetti2020]
Levodopa (20 mg/mL) - dopamine precursor that crosses the [blood-brain barrier](/entities/blood-brain-barrier)
Carbidopa (5 mg/mL) - peripheral DOPA decarboxylase inhibitor that prevents peripheral conversion to dopamine
Pharmacokinetic Advantages
Continuous infusion provides:
Stable dopaminergic stimulation
Reduced pulsatile receptor activation
Minimized end-of-dose "wearing off"
Decreased dyskinesia development
Clinical Applications
Indications
LCIG is indicated for patients with advanced Parkinson's disease who:[@fernandez2020]
Experience motor fluctuations ("wearing off") despite optimized oral therapy
Have inadequate symptom control with oral levodopa
Are not candidates for deep brain stimulation
Have good cognitive function (no significant dementia)
Efficacy
Randomized controlled trials demonstrate:
"Off" time reduction: 4-6 hours/day reduction in time with poor mobility
"On" time increase: 4-7 hours/day increase in good motor function
Dyskinesia improvement: 50-70% reduction in dyskinesia severity
Quality of life: PDQ-39 improvement of 10-20 points
Motor score improvement: UPDRS Part III OFF-medication improvement of 20-30%
Long-term Outcomes
Studies show benefits maintained over 5-7 years of continuous use:[@zibetti2020]
Sustained motor symptom control
Continued reduction in motor fluctuations
Stable or improved quality of life measures
Reduced need for oral medications
Surgical Procedure
PEG/J Tube Placement
Endoscopic procedure: Performed by gastroenterologist
Gastrostomy: Stomach tube placed percutaneously
Jejunostomy: Inner tube advanced past pylorus into duodenum
External connection: Connected to portable pump
Pump Operation
Portable pump: Worn on body, delivers gel continuously
Morning bolus: Large initial dose to rapidly achieve "on" state
Continuous infusion: Steady delivery throughout the day
Adjustable rates: Titrated to individual patient needs
The study of Levodopa Carbidopa Intestinal Gel (Duodopa) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions